Patents by Inventor Bo Niklasson

Bo Niklasson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9044549
    Abstract: A syringe dispenser may include a plunger having an outer threading, a barrel adapted to contain liquid or semisolid fluid or any other material to be dispensed and to receive the plunger, the plunger being movably attached to the barrel, and a nut having an inner threading. The nut may at least partly enclose the plunger and the barrel, such that the inner threading of the nut engages with the outer threading of the plunger. A stand, an application plate, and a method of dispensing a controlled and measurable amount of liquid or semisolid fluid from a syringe dispenser are also disclosed.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: June 2, 2015
    Assignee: NOVISCENS AB
    Inventor: Bo Niklasson
  • Publication number: 20130043282
    Abstract: A syringe dispenser may include a plunger having an outer threading, a barrel adapted to contain liquid or semisolid fluid or any other material to be dispensed and to receive the plunger, the plunger being movably attached to the barrel, and a nut having an inner threading. The nut may at least partly enclose the plunger and the barrel, such that the inner threading of the nut engages with the outer threading of the plunger. A stand, an application plate, and a method of dispensing a controlled and measurable amount of liquid or semisolid fluid from a syringe dispenser are also disclosed.
    Type: Application
    Filed: April 19, 2011
    Publication date: February 21, 2013
    Applicant: NOVISCENS AB
    Inventor: Bo Niklasson
  • Patent number: 8231879
    Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barre Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: July 31, 2012
    Inventor: Bo Niklasson
  • Publication number: 20120027776
    Abstract: An isolated nucleic acid molecule is disclosed, including a nucleotide sequence selected from the nucleotide sequence of (a) Ljungan virus 87-012, (b) Ljungan virus 145SL, (c) Ljungan virus 174F, and (d) a fragment of nucleotide sequences (a)-(c). Also disclosed are polypeptides encoded by the isolated nucleic acid, which are useful in preparing vaccines and antibodies to prevent or inhibit conditions caused by Ljungan virus, including diabetes.
    Type: Application
    Filed: June 1, 2009
    Publication date: February 2, 2012
    Inventors: Bo Niklasson, Ake Lernmark
  • Publication number: 20110300149
    Abstract: The present invention relates to a new group of Ljungan viruses, proteins expressed by the viruses, antibodies to the viruses and proteins, vaccines against the viruses, diagnostic kits for detecting the viruses, uses of the viruses, proteins, antibodies and vaccines in therapy, uses of the viruses, proteins, antibodies and vaccines in treating diseases caused by the viruses and methods of treatment for treating diseases caused by the viruses.
    Type: Application
    Filed: December 23, 2009
    Publication date: December 8, 2011
    Applicant: Apodemus AB
    Inventors: Bo Niklasson, Conny Tolf, Michael Lindberg
  • Publication number: 20110033418
    Abstract: A method of prophylactic and/or therapeutic treatment of a mammal is provided for treating a disease that is caused by a Ljungan virus infection. The method comprises administration to the mammal of an antivirally effective amount of ribavirin or a derivative thereof effective against the Ljungan virus and pleconaril or a derivative thereof effective against the Ljungan virus to eliminate or inhibit proliferation of said virus in said mammal and at the same time prevent and/or treat said disease in said mammal. Also provided is a composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and pleconaril or a derivative thereof effective against a Ljungan virus and a kit relating to this composition. Further, a method is provided for treating Ljungan virus infection comprising administering ribavirin or a derivative thereof effective against the Ljungan virus as well as a composition and a kit comprising ribavirin.
    Type: Application
    Filed: June 17, 2010
    Publication date: February 10, 2011
    Inventor: Bo Niklasson
  • Patent number: 7855277
    Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: December 21, 2010
    Assignee: Apodemus AB
    Inventor: Bo Niklasson
  • Patent number: 7803525
    Abstract: The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: September 28, 2010
    Assignees: Apodemus AB, Robert-Koch Institut
    Inventors: Bo Niklasson, Andreas Nitsche, Oliver Donoso Mantke, Matthias Niedrig
  • Patent number: 7560609
    Abstract: The invention relates to an animal model for diabetes and a method for obtaining said animal model. The invention also relates to the uses of the animal model for screening for or testing compounds for treating or preventing diabetes symptoms. The invention further relates to an assay for determining an individual's susceptibility to developing diabetes. The invention also relates to nucleic acid molecules isolated from Ljungan virus and to polypeptides encoded by any portion of said nucleic acid molecule.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: July 14, 2009
    Inventors: Bo Niklasson, Åke Lernmark
  • Publication number: 20090155769
    Abstract: The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.
    Type: Application
    Filed: March 15, 2006
    Publication date: June 18, 2009
    Inventors: Bo Niklasson, Andreas Nitsche, Oliver Donoso Mantke, Matthias Niedrig
  • Publication number: 20090004143
    Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.
    Type: Application
    Filed: June 23, 2008
    Publication date: January 1, 2009
    Inventor: Bo Niklasson
  • Patent number: 7442380
    Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: October 28, 2008
    Assignee: Apodemus AB
    Inventor: Bo Niklasson
  • Publication number: 20070003574
    Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 4, 2007
    Inventor: Bo Niklasson
  • Publication number: 20070003573
    Abstract: (I) SEQ ID NO: 1 (Ljungan 87-012) AGTCTAGTCT TATCTTGTAT GTGTCCTGCA CTGAACTTGT TTCTGT CTCT 50? GGAGTGCTCT ACACTTCAGT AGGGGCTGTA CCCGGGCGGT CCCACT CTTC 100 ACAGGAATCT GCACAGGTGG CTTTCACCTC TGGACAGTGC ATTCCA CACC 150 CGCTCCACGG TAGAAGATGA TGTGTGTCTT TGCTTGTGAA AAGCTT GTGA 200 AAATCGTGTG TAGGCGTAGC GGCTACTTGA GTGCCAGCGG ATTACC CCTA 250 GTGGTAACAC TAGC A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (1) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease.
    Type: Application
    Filed: June 7, 2006
    Publication date: January 4, 2007
    Inventor: Bo Niklasson
  • Patent number: 7101554
    Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatique Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: September 5, 2006
    Assignee: Microtus AB
    Inventor: Bo Niklasson
  • Publication number: 20060018876
    Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.
    Type: Application
    Filed: August 22, 2005
    Publication date: January 26, 2006
    Inventor: Bo Niklasson
  • Publication number: 20050233311
    Abstract: The present invention relates to a new family of viruses within the Picornavirus family. The present invention also relates to an isolated nucleic acid from said virus or fragments of said nucleic acid. The present invention also relates to an isolated protein of said virus or an immunogenic fragment thereof. The invention also relates to antibodies or antigen-binding fragments of such antibodies directed against said virus. The present invention also relates to diagnostic kits. The present invention also relates to a method of detecting the presence of said virus in a subject suspected of having a viral infection.
    Type: Application
    Filed: April 23, 2003
    Publication date: October 20, 2005
    Inventors: Michael Lindberg, Susanne Johansson, Bo Niklasson
  • Publication number: 20050043648
    Abstract: An epicutaneous test plaster, which is intended for removable adhesion to a skin portion of a person subjected to testing, has a flexible carrier (10) with a medical adhesive layer (12) and a number of test chambers (31). The test chambers contain a filter element (17) for absorption of allergen and are oriented with their opening directed away from the flexible carrier (10). A removable cover layer (27, 32) extends over all the test chambers and the carrier (10) and is removably secured to them by means of the adhesive layer (12) of the carrier. According to the invention, the test chambers (31) are formed as separate chambers, which are each separately fixed to the carrier and which are made up of a number of different sub-layers (13, 17, 19, 20, 24, 26).
    Type: Application
    Filed: January 16, 2003
    Publication date: February 24, 2005
    Inventor: Bo Niklasson
  • Publication number: 20040265793
    Abstract: The invention relates to an animal model for diabetes and a method for obtaining said animal model. The invention also relates to the uses of the animal model for screening for or testing compounds for treating or preventing diabetes symptoms. The invention further relates to an assay for determining an individual's susceptibility to developing diabetes. The invention also relates to nucleic acid molecules isolated from Ljungan virus and to polypeptides encoded by any portion of said nucleic acid molecule.
    Type: Application
    Filed: August 12, 2004
    Publication date: December 30, 2004
    Inventors: Bo Niklasson, Ake Lernmark
  • Patent number: 6562802
    Abstract: A composition is described, which comprises a cationic, hydrophilic, amine containing cationic derivatives of native chitosan; bound to an anionic scavenger substance, which is either (a) selected from the group consisting of anionic ethylene amine compounds, tetraazacycloalkane-N,N,N,N-tetraacetic acids; and polymer derivatives of porphyrines, or, (b) in the case of use in an UV radiation absorbing formulation, an antiviral, antifungal or anti-inflammatory formulation, an endogenous compound wherein cationic derivatives of native chitosan are not covalently bound to DTPA or EDTA; the amount of EDTA exceeds 0.5 wight percent; and taurine and taurine derivatives are not present.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: May 13, 2003
    Assignee: Noviscens AB
    Inventors: Benny Johansson, Bo Niklasson